DE1809119A1 - Magnesium aspartate prepn for the treatment - of infarction conditions - Google Patents
Magnesium aspartate prepn for the treatment - of infarction conditionsInfo
- Publication number
- DE1809119A1 DE1809119A1 DE19681809119 DE1809119A DE1809119A1 DE 1809119 A1 DE1809119 A1 DE 1809119A1 DE 19681809119 DE19681809119 DE 19681809119 DE 1809119 A DE1809119 A DE 1809119A DE 1809119 A1 DE1809119 A1 DE 1809119A1
- Authority
- DE
- Germany
- Prior art keywords
- magnesium
- treatment
- prepn
- magnesium aspartate
- infarction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
- F21S8/00—Lighting devices intended for fixed installation
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
- F21S8/00—Lighting devices intended for fixed installation
- F21S8/08—Lighting devices intended for fixed installation with a standard
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Infarktprophylaktikum Die vorliegende Erfindung betrifft ein Infarktprophylaktikum, das durch einen Gehalt an Magnesiummonoaspartahydrochlorid gekennzeichnet istc Magnesiummonoasparthydrochlorid der Formel ist eine farblose kristalline Substans (glasklare Platten und Säulen), die in Porm einer 1 %igen wässrigen Lösung ein pH von 4,5 - 4,8 ergibt und als 6 %ige 1-n-HCl-Lösung eine spezifische Drehung von +12,5 + 2 besitzt. Der Mischschmelzpunkt dieser Verbindung mit Dicyaniamid beträgt 188°C. Die Löslichkeit in Wasser beträgt 1:5 (kalt), während die Verbindung in Alkohol, Aceton und Chloroform schwer löslich ist.Infarct prophylactic agent The present invention relates to an infarct prophylactic agent which is characterized by a content of magnesium monoaspartahydrochloride c magnesium monoaspartic hydrochloride of the formula is a colorless crystalline substance (crystal clear plates and columns), which in the form of a 1% aqueous solution gives a pH of 4.5-4.8 and as a 6% 1-n-HCl solution a specific rotation of +12 , 5 + 2 owns. The mixed melting point of this compound with dicyaniamide is 188 ° C. The solubility in water is 1: 5 (cold), while the compound is sparingly soluble in alcohol, acetone and chloroform.
Das erfindungsgemässe Magnesiummonoaspartathydrochlorid lösst sich aus Magnesiumdiaspartat durch Zugabe von Chlorwasserstoff nach folgendem Reaktionsschama herstellen: Die Chlorwasserstoffsäure auß der Lösung des Magnesiumdiaspartate schnell zugesetzt werden, denn sobald Asparaginsäure ausfällt, bildet sich eine thixotrope Masse, welche sich nur schwer durchmischen laßt.The magnesium monoaspartate hydrochloride according to the invention can be prepared from magnesium diaspartate by adding hydrogen chloride according to the following reaction scheme: The hydrochloric acid from the solution of the magnesium diaspartate can be added quickly, because as soon as aspartic acid precipitates, a thixotropic mass is formed, which is difficult to mix.
Die Reaktion wird am zweckmäßigsten in einem wäßrigen Nediui unter Verwendung der stöchiometrischen Mangen der N tanten durchgeführt. Die ausgefallene Asparaginsäure wird nach beendeter Umsetzung abfiltriert. Naoh Einengen des Filtrats kristallisiert das erfindungsgemäße Magnesiummonoaspartathydrochlorid aus. Die Verbindung Itapun oh Ueblichen Methoden, beispielsweise durch Unkristallisation, gereinigt werden.The reaction is most conveniently carried out in an aqueous Nediui Using the stoichiometric amounts of the N aunts carried out. The unusual one Aspartic acid is filtered off after the reaction has ended. Then concentrate the filtrate The magnesium monoaspartate hydrochloride according to the invention crystallizes out. The connection Itapun was purified by the usual methods, for example by recrystallization will.
Das erfindungsgemäße Magnesiummonoaspartathydrochlorid zeichnet sich in Überraschender Weise durch eine sehr große Komplexstabilität aus. Diese Tatsache ist insofern besonders überraschend, als das entsprechende Magnesiumglutamathydrochlorid eine wesentlich geringere Komplexstabilität besitzt.The magnesium monoaspartate hydrochloride according to the invention is distinguished Surprisingly characterized by a very high complex stability. this fact is particularly surprising as the corresponding magnesium glutamate hydrochloride has a much lower complex stability.
Daher eignet sich die erfindungsgemäße Verbindung in hervorragender Weise zur Magnesiumtherapie, da diese Verbindung aufgrund der geschilderten Eigenschaften die Gewähr rur eine weitgehende Resorption und gute Organverteilung von Magnesium biotot und in dieser Hinsicht allen bisher bekanten anorganischen und organischen Verbindungen überlegen ist.Therefore, the compound of the present invention is particularly useful Way to magnesium therapy, as this compound is due to the properties described the guarantee of extensive absorption and good organ distribution of magnesium biotot and in this respect all inorganic and organic known so far Connections is superior.
Magnesiumverbindungen werden für die Harzinfarktprophylaxe seit einigen Jahren empfohlen. Der Grad des therapeutisch zu erwartcndon Effekts ist abhängig von der Magnesiummenge, die in den Körper eingebracht werden kann. Infolge der hohen Komplexkonstante wird das erfindungsgemäße verwendeteMagnesiummonoaspartathydroohlorid erheblich besser als alle bisher bekannten Magnesiumverbindungen resorbiert, so dass der Wirkungsgrad dieser Verbindung über demjenigen aller bisher bekannten Magnesiumverbindungen liegt.Magnesium compounds have been used for resin infarction prophylaxis for some Recommended for years. The degree of the therapeutically expected effect depends on the amount of magnesium that can be brought into the body. As a result of the high The magnesium monoaspartate hydrochloride used in the present invention becomes the complex constant considerable better absorbed than all previously known magnesium compounds, so that the efficiency this compound is above that of all previously known magnesium compounds.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681809119 DE1809119C3 (en) | 1968-11-15 | 1968-11-15 | Heart attack prophylactic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19681809119 DE1809119C3 (en) | 1968-11-15 | 1968-11-15 | Heart attack prophylactic |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1809119A1 true DE1809119A1 (en) | 1970-06-11 |
DE1809119B2 DE1809119B2 (en) | 1973-05-17 |
DE1809119C3 DE1809119C3 (en) | 1973-12-20 |
Family
ID=5713434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19681809119 Expired DE1809119C3 (en) | 1968-11-15 | 1968-11-15 | Heart attack prophylactic |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE1809119C3 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855289A (en) * | 1984-06-04 | 1989-08-08 | Wester Per O | Combination of two active substances |
CN105712895A (en) * | 2014-12-04 | 2016-06-29 | 辽宁药联制药有限公司 | Preparation method for magnesium aspartate hydrochloride trihydrate |
CN106883135A (en) * | 2015-12-16 | 2017-06-23 | 辽宁药联制药有限公司 | A kind of method for preparing MAH bulk drug |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2720288C2 (en) * | 1977-05-05 | 1984-02-16 | Verlapharm v. Ehrlich AG, Emmenbrücke | Use of magnesium salts for the production of preparations for treating farm animals |
DE3238118A1 (en) * | 1982-10-14 | 1984-04-19 | Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing | METHOD FOR PRODUCING COMPLEX COMPOUNDS FROM AMINODICARBONIC ACIDS, DUAL VALUE METALIONS AND HALOGENIDIONS |
DE3814856A1 (en) * | 1988-05-02 | 1989-11-16 | Verla Pharm | MEANS FOR PROPHYLAXIS OF THE HEART INFARM AND FOR PREVENTING THE REINFARK |
-
1968
- 1968-11-15 DE DE19681809119 patent/DE1809119C3/en not_active Expired
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855289A (en) * | 1984-06-04 | 1989-08-08 | Wester Per O | Combination of two active substances |
CN105712895A (en) * | 2014-12-04 | 2016-06-29 | 辽宁药联制药有限公司 | Preparation method for magnesium aspartate hydrochloride trihydrate |
CN106883135A (en) * | 2015-12-16 | 2017-06-23 | 辽宁药联制药有限公司 | A kind of method for preparing MAH bulk drug |
Also Published As
Publication number | Publication date |
---|---|
DE1809119C3 (en) | 1973-12-20 |
DE1809119B2 (en) | 1973-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2745083A1 (en) | HYDROXYDIPHOSPHONIC ACIDS | |
DE1809119A1 (en) | Magnesium aspartate prepn for the treatment - of infarction conditions | |
DE1925230C3 (en) | Process for the production of the antibiotic streptozotocin | |
DE3039997A1 (en) | PHOSPHONOHYDROXYACETONITRILE, A METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS AN INTERMEDIATE PRODUCT FOR THE PRODUCTION OF MEDICINAL PRODUCTS | |
DE944943C (en) | Process for the preparation of sodium perborate trihydrate | |
DE2430550C2 (en) | Ethanol-water solvates of sodium hexametaphosphate complexes of α-6-deoxy-5-hydroxy-tetracycline and a process for their preparation | |
DE1809120A1 (en) | Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments | |
DE1145588B (en) | Process for the production of pure sodium hypophosphite | |
DE1809121A1 (en) | Magnesium monoaspartate hydrobromide useful - as a sectative or tranquilliser | |
DE944953C (en) | Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid | |
DE595928C (en) | Process for the production of thiourea | |
DE525651C (en) | Process for the production of stable complex compounds of pentavalent antimony which are soluble in water | |
DE713079C (en) | Process for the preparation of clusters of 4-aminobenzenesulfonamides | |
DE2745084A1 (en) | 5-Keto-piperazine-2,2-di:phosphonic acid derivs. - useful as chelating agents e.g. in water treatment, for providing trace elements and treating metabolic disorders | |
AT216141B (en) | Process for the preparation of the new dihydrate of the calcium salt of phenoxymethylpenicillin | |
DE1809118A1 (en) | Mono magnesium aspartate hydrofluoride | |
DE2501959C2 (en) | Method of making K? X? H? 3?? -?? X? PO? 4? | |
DE398406C (en) | Process for the production of aluminum formate solutions | |
DE1924174C3 (en) | Magnesium Orotate Glycinate | |
DE955592C (en) | Process for the preparation of crystallizable mixed salts of dihydrostreptomycin which are difficult to dissolve in water | |
DE870276C (en) | Process for the preparation of a double salt of p-amino-salicylic acid | |
DE1270540B (en) | Process for the preparation of water-soluble complex compounds of aliphatic oxycarboxylic acids | |
DE2318043C3 (en) | Bis-square brackets on 4,7-dihydroxycumarinyl- (3) square brackets acetic acid and its pharmacologically acceptable salts as well as processes for their production and pharmaceuticals containing these compounds | |
DE947333C (en) | Process for the production of crystallized islet hormone preparations | |
DE637188C (en) | Process for the production of theophylline or theobromine compounds of mercury compounds of the urethane series |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SH | Request for examination between 03.10.1968 and 22.04.1971 | ||
C3 | Grant after two publication steps (3rd publication) |